消息面上，1月7日，工信部等八部门联合印发《"人工智能+制造"专项行动实施意见》。其中提出，到 2027年，我国人工智能关键核心技术实现安全可靠供给，产业规模和赋能水平稳居世界前列。推动3至5 个通用大模型在制造业深度应用，形成特色化、全覆盖的行业大模型，打造100个工业领域高质量数据 集，推广500个典型应用场景。机构表示，国家积极推动AI应用发展，有望持续拉动对于国内AI算力的 需求。 AI应用概念9日盘中大幅走高，截至发稿，易点天下20%涨停，昆仑万维逼近涨停，星环科技涨超16% 创历史新高，值得买等涨超10%。 ...

Group 1 - The digital media sector increased by 1.7% on January 8, with Guomai Culture leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] - Guomai Culture's stock price rose by 5.28% to 13.55, with a trading volume of 196,300 shares and a transaction value of 264 million yuan [1] Group 2 - The net outflow of main funds in the digital media sector was 64.15 million yuan, while retail investors saw a net inflow of 147 million yuan [1] - The stock "Zhidingmai" had a main fund net inflow of 67.59 million yuan, but retail investors experienced a net outflow of 35.76 million yuan [2] - "Guomai Culture" had a main fund net inflow of 17.50 million yuan, with retail investors seeing a net outflow of 11.50 million yuan [2]

诺安积极回报混合A（001706）基金经理为刘慧影。 截至发稿，刘慧影累计任职时间3年160天，现任基金资产总规模236.34亿元，任职期间最佳基金回报 75.14%， 任职期间最差基金回报12.83%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从值得买十大流通股东角度 数据显示，诺安基金旗下1只基金位居值得买十大流通股东。诺安积极回报混合A（001706）三季度新 进十大流通股东，持有股数148.98万股，占流通股的比例为1.22%。根据测算，今日浮盈赚取约342.65 万元。 诺安积极回报混合A（001706）成立日期2016年9月22日，最新规模13.65亿。今年以来收益4.85%，同 类排名1953/8825；近一年收益7.16%，同类排名6755/8084；成立以来收益109.6%。 1月8日，值得买涨5.11%，截至发稿，报47.34元/股，成交10.00亿元，换手率18.00%，总市值94.14亿 元。 资料显示，北京值得买科技股 ...

Core Viewpoint - The value of the "Hui Min Bao" insurance product depends on individual needs, including age, health status, and budget considerations [1] Group 1: Characteristics of Hui Min Bao - Hui Min Bao is characterized by its inclusivity, with premiums generally ranging from tens to over two hundred yuan annually, and relaxed underwriting conditions that typically do not limit age, occupation, or health status [2] - It is particularly suitable for elderly individuals, those with pre-existing conditions who find it difficult to obtain commercial insurance, budget-conscious young people, and those looking to enhance their existing insurance coverage [2] Group 2: Highlights of Hui Min Bao - In 2026, various local Hui Min Bao products will expand their special drug lists, lower claims thresholds, and broaden the insured population to attract participants. For instance, the "Beijing Universal Health Insurance" will include 159 special drugs, featuring 57 domestically listed special drugs and 65 overseas special drugs not yet available in China, along with 37 new innovative drugs and therapies [3] - Some products offer additional services such as appointment assistance, home care, dental cleaning, cancer screening, and traditional Chinese medicine preparation, allowing policyholders to choose according to their needs [3] Group 3: Claims and Limitations - Hui Min Bao, while a government-guided and commercially operated inclusive insurance product, faces challenges such as high claims thresholds, typically ranging from 10,000 to 20,000 yuan. If the amount after medical insurance reimbursement does not meet the deductible, no compensation will be provided [5] - The product is designed for broad coverage and low premiums, primarily serving as a safety net for major illnesses rather than comprehensive coverage, and should not replace basic medical insurance or be equated with high-coverage commercial health insurance [5]

Market Overview - The digital media sector experienced a decline of 0.52% on January 7, with Fengyuzhu leading the drop [1] - The Shanghai Composite Index closed at 4085.77, up 0.05%, while the Shenzhen Component Index closed at 14030.56, up 0.06% [1] Individual Stock Performance - Zhangyue Technology (603533) closed at 24.77, up 4.47% with a trading volume of 544,500 shares and a transaction value of 1.338 billion yuan [1] - Zhidema (300785) closed at 45.04, up 1.53% with a trading volume of 241,000 shares and a transaction value of 1.081 billion yuan [1] - People's Daily Online (603000) closed at 19.85, down 0.25% with a trading volume of 184,200 shares and a transaction value of 368 million yuan [1] - Fengyuzhu (603466) closed at 9.98, down 2.54% with a trading volume of 265,700 shares and a transaction value of 268 million yuan [2] Capital Flow Analysis - The digital media sector saw a net outflow of 531 million yuan from institutional investors, while retail investors had a net inflow of 490 million yuan [2] - The individual stock capital flow indicates that Zhidema had a net outflow of 25.05 million yuan from institutional investors, while retail investors contributed a net inflow of 53,700 yuan [3] - Zhangyue Technology experienced a net inflow of 14.84 million yuan from institutional investors, with a net outflow of 619,080 yuan from speculative funds [3]

Core Viewpoint - The "Hui Min Bao" insurance product, effective from January 1, 2026, is a government-guided, commercially operated universal insurance aimed at providing affordable coverage, but it faces challenges such as high claims thresholds [1]. Group 1: Affordability and Accessibility - The main feature of Hui Min Bao is its affordability, with annual premiums generally ranging from tens to over two hundred yuan [2]. - The insurance has lenient eligibility criteria, typically not restricting based on age, occupation, or health status, making it accessible for elderly individuals, those with pre-existing conditions, budget-conscious young people, and those seeking to expand their existing coverage [2]. Group 2: Benefits and Features - In 2026, various local Hui Min Bao products will enhance their appeal by expanding the list of covered special medications, lowering claims thresholds, and broadening the insured population [3]. - For instance, the "Beijing Universal Health Insurance" will include 159 types of special medications, featuring 57 domestically listed drugs and 65 overseas drugs not yet available in China, along with an additional 37 new special medications [3]. - Some products will also offer additional services such as appointment assistance, home care, dental cleaning, cancer screening, and traditional Chinese medicine preparation, allowing policyholders to choose services that meet their needs [3]. Group 3: Claims and Considerations - The typical claims threshold for Hui Min Bao ranges from 10,000 to 20,000 yuan, and if the insured does not meet the deductible after reimbursement from basic medical insurance, they will not receive compensation [5]. - The decision to purchase Hui Min Bao should be based on individual needs, considering factors such as age, health status, budget, and understanding the specific deductible, reimbursement ratios, and covered medication lists [5].

Core Viewpoint - The company "值得买" has shown a positive stock performance with a 2.01% increase on January 5, 2025, and a total market capitalization of 8.89 billion yuan, despite some net outflow of funds [1] Group 1: Financial Performance - For the period from January to September 2025, the company achieved operating revenue of 806 million yuan, a year-on-year decrease of 20.37%, while the net profit attributable to shareholders increased by 253.49% to 13.45 million yuan [2] - Cumulative cash distribution since the company's A-share listing amounts to 216 million yuan, with 84.18 million yuan distributed over the last three years [3] Group 2: Shareholder and Market Activity - As of December 19, 2025, the number of shareholders decreased by 3.04% to 41,000, while the average circulating shares per person increased by 3.14% to 2,984 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 6.25 million shares to 7.96 million shares, and new entrants such as 诺安积极回报混合A and 汇添富科技创新混合A [3] Group 3: Business Overview - The company operates a content-driven e-commerce platform, "什么值得买" (www.smzdm.com), providing promotional services for e-commerce and brand companies, with revenue sources including information promotion (41.83%), internet marketing platform services (28.38%), operational service fees (27.62%), brand marketing (2.00%), and product sales (0.17%) [1] - The company is classified under the media-digital media-portal website sector and is associated with concepts such as Kimi, 小红书, AI language database, and network marketing [2]

Investment Rating - The industry investment rating is "Buy" [3] Core Insights - The report highlights that AI applications are expected to enter a new phase of intensive catalysis, with both industrial logic and catalysts presenting opportunities. Long-term prospects for domestic large models catching up with overseas counterparts and further application deployment are positive. The report recommends leading internet companies like Alibaba and Tencent, as well as niche application leaders such as Kuaishou and Meitu [7][10]. Summary by Sections Domestic AI Dynamics Tracking - The report tracks domestic AI large model product data, indicating that the web traffic for major AI models remains stable, with some fluctuations. For instance, Kimi had 7.99 million visits, down 7.83% week-on-week, while DeepSeek led with 66.33 million visits, down 5.06% [21][23]. - The report also notes that the average daily visit duration for Kimi is around 8 minutes, while other models like DeepSeek and Tongyi Qianwen are around 5 minutes [13]. Key Company Events - The report mentions that GLM-4.7 has topped the Artificial Analysis global open-source ranking, achieving a score of 68 in the Artificial Analysis Intelligence Index, making it the top model in both open-source and domestic categories [39][40]. Overseas AI Dynamics Tracking - In the overseas market, ChatGPT continues to lead in web traffic, while Claude's traffic has seen a decline. The report emphasizes the competitive landscape of AI models globally [41].

Core Insights - The CXO sector in A/H shares shows signs of fundamental recovery ahead of expectations in 2025 after three years of valuation downgrades [1] - The recovery is uneven, with the clinical CRO segment still facing challenges, indicating a divergence in industry recovery [1][7] Group 1: Financial Performance - WuXi AppTec (药明康德) reported a revenue of 32.857 billion yuan in the first three quarters of 2025, a year-on-year increase of 18.61%, and a net profit of 12.076 billion yuan, up 84.84% [1] - The company had a backlog of orders amounting to 59.880 billion yuan as of September 2025, reflecting a 37.2% year-on-year growth [1] - The average price of clinical research services in China has decreased by approximately 30% since 2022, impacting gross and net profit margins [2] Group 2: Order Fulfillment and Business Model - The business model of CXO leads to a natural lag in order fulfillment, with revenue recognition often taking multiple quarters or years [2] - WuXi AppTec's backlog at the end of 2024 was 49.310 billion yuan, 1.26 times its revenue for that year, indicating visible future revenue growth potential [2] - The order-to-revenue ratio is crucial for assessing conversion efficiency, with a healthy range identified between 1.2 to 1.3 times [3] Group 3: Market Dynamics and Challenges - The global pharmaceutical R&D investment continues to grow, but structural fluctuations are evident, particularly among innovative drug startups [1] - The clinical CRO segment is heavily influenced by funding constraints and project strategy adjustments, leading to a situation where project numbers increase but individual project outputs decline [8] - The international expansion of clinical CROs raises higher standards for organizational capability and compliance, making short-term recovery challenging [8] Group 4: Emerging Opportunities - The global expansion of GLP-1 and related indications has led to unexpected order increases in upstream peptide and related processes, maintaining high demand in 2025 [9] - Core stock Novartis Bio (诺泰生物) achieved a revenue of 1.527 billion yuan in the first three quarters of 2025, with a net profit of 445 million yuan, reflecting a year-on-year growth of 21.95% and 26.92% respectively [9] - The market for cell and gene therapy (CGT) is still growing, but profitability remains elusive, with significant investments required before becoming a core profit driver [10][11]

Group 1 - The core viewpoint emphasizes that Beijing's foreign trade is leveraging innovation as a key to navigate global trade changes, aligning with the "14th Five-Year Plan" for trade power deployment [6] - Companies like JD.com, Douyin, and Zhidema Technology are actively engaging in cross-border e-commerce, utilizing AI and content ecosystems to optimize the entire outbound process [6] - The Beijing Digital Economy Outbound Innovation Service Base is establishing a "1+3+N" ecosystem to provide comprehensive support for companies going abroad [6] Group 2 - Enterprises are deepening the integration of domestic and foreign trade through initiatives like "export to domestic sales," reinforcing their development resilience [6] - The combination of policy support and digital empowerment is facilitating Beijing's transition from traditional OEM to "independent R&D + global branding," becoming a crucial pillar for high-quality development in the dual circulation pattern [6]